Related Experiment Videos
Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors
U Rodeck1, M Herlyn, H Koprowski
1Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104.
Abstract:
Monoclonal antibodies (MAbs) to the human epidermal growth factor (EGF) receptor, the type I insulin-like growth factor (IGF) receptor, and the nerve growth factor (NGF) receptor were used to study the growth regulation of malignant cells. Anti-EGF receptor MAb 425 inhibited the growth of A 431 squamous carcinoma cells which express high numbers of EGF receptors on their surfaces. Growth inhibition induced by MAb 425 was accompanied by alterations of the cell-cycle distribution of these cells, indicating the ability of a monoclonal antibody to act as a biologically active ligand. Growth stimulation of melanoma cells by EGF was unrelated to EGF receptor expression on the cell surface. Insulin- and IGF-I-induced growth stimulation of melanoma cells was inhibited by MAb alpha IR-3 which reacts with the type I IGF receptor. This result indicates that the type I IGF receptor mediated growth stimulation not only by IGF-I but also by insulin. Normal melanocytes and cells of all stages of tumor progression expressed in tissue culture the receptor for NGF, but no effect on the growth of these cells has been observed.
Insights
Monoclonal antibodies targeting growth factor receptors can inhibit malignant cell growth. These antibodies demonstrate potential as therapeutic agents by modulating cell growth and signaling pathways.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Malignant cell proliferation is often regulated by growth factor receptors.
- Understanding receptor-ligand interactions is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the role of specific growth factor receptors in malignant cell growth regulation.
- To evaluate the efficacy of monoclonal antibodies (MAbs) against these receptors as potential therapeutic agents.
Main Methods:
- Utilized MAbs targeting the human epidermal growth factor (EGF) receptor, type I insulin-like growth factor (IGF) receptor, and nerve growth factor (NGF) receptor.
- Assessed the impact of MAbs on the growth of various cancer cell lines, including squamous carcinoma and melanoma cells.
- Analyzed cell-cycle distribution alterations in response to MAb treatment.
Main Results:
- Anti-EGF receptor MAb 425 inhibited growth of A431 squamous carcinoma cells, indicating MAbs can act as biologically active ligands.
- Insulin and IGF-I-induced growth stimulation of melanoma cells was inhibited by MAb alpha IR-3 targeting the type I IGF receptor.
- NGF receptor was expressed on melanocytes and tumor cells, but no growth effect was observed.
Conclusions:
- Monoclonal antibodies targeting growth factor receptors can effectively inhibit malignant cell proliferation.
- The type I IGF receptor mediates growth stimulation by both IGF-I and insulin, suggesting broader therapeutic targeting potential.
- Further research into MAb-mediated growth regulation is warranted for targeted cancer therapy development.